{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T21:49:20Z","timestamp":1794952160304,"version":"4.9.1"},"reference-count":153,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1693,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1111\/j.1365-2036.2010.04566.x","type":"journal-article","created":{"date-parts":[[2011,1,12]],"date-time":"2011-01-12T06:33:02Z","timestamp":1294813982000},"page":"634-649","source":"Crossref","is-referenced-by-count":65,"title":["Review article: endpoints used in functional dyspepsia drug therapy trials"],"prefix":"10.1111","volume":"33","author":[{"given":"D.","family":"Ang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. J.","family":"Talley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Simren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Boeckxstaens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Tack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,1,12]]},"reference":[{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB1|cit1","first-page":"576","article-title":"Management of dyspepsia: report of a working party","volume":"1","author":"Colin-Jones","year":"1988","journal-title":"Lancet"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB2|cit2","first-page":"145","article-title":"Functional dyspepsia: a classification with guidelines for diagnosis and management","volume":"4","author":"Talley","year":"1991","journal-title":"Gastrointest Int"},{"issue":"Suppl. II","key":"10.1111\/j.1365-2036.2010.04566.x-BIB3|cit3","first-page":"37","article-title":"Functional gastroduodenal disorders","volume":"45","author":"Talley","year":"1999","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1053\/j.gastro.2005.11.059","article-title":"Functional gastroduodenal disorders","volume":"130","author":"Tack","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB5|cit5","first-page":"145","article-title":"Identification of subgroups of functional gastrointestinal disorders","volume":"4","author":"Drossman","year":"1991","journal-title":"Gastroenterol Int"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"965","DOI":"10.7326\/0003-4819-108-6-865","article-title":"Non-ulcer dyspepsia: potential causes and pathophysiology","volume":"108","author":"Talley","year":"1988","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/oxfordjournals.aje.a116483","article-title":"Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders","volume":"136","author":"Talley","year":"1992","journal-title":"Am J Epidemiol"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1111\/j.1572-0241.2004.40052.x","article-title":"The prevalence and risk factors of functional dyspepsia in a multiethnic population in the United States","volume":"99","author":"Shaib","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB9|cit9","unstructured":"US Food and Drug Administration (FDA) Guidance for Industry. Patient reported outcome measures: use in medical product development to support labeling claims 2006"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1053\/j.gastro.2005.11.058","article-title":"Design of treatment trials for functional gastrointestinal disorders","volume":"130","author":"Irvine","year":"2006","journal-title":"Gastroenterology"},{"issue":"Suppl. 199","key":"10.1111\/j.1365-2036.2010.04566.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3109\/00365529309098356","article-title":"A systematic overview (meta-analysis) of outcome measures in Helicobacter pylori gastritis trials and functional dyspepsia","volume":"28","author":"Veldhuyzen van Zanten","year":"1993","journal-title":"Scan J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/0016-5085(94)90007-8","article-title":"A critique of therapeutic trials in Helicobacter pylori-positive functional dyspepsia","volume":"106","author":"Talley","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB13|cit13","first-page":"660","article-title":"Drug treatment of functional dyspepsia: a systematic analysis of trial methodology with recommendations for design of future trials","volume":"91","author":"Veldhuyzen van Zanten","year":"1996","journal-title":"Am J Gastroenterol"},{"issue":"Suppl. IV","key":"10.1111\/j.1365-2036.2010.04566.x-BIB14|cit14","first-page":"23","article-title":"Assessment of outcome in dyspepsia: has progress been made?","volume":"50","author":"Veldhuyzen van Zanten","year":"2002","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1053\/j.gastro.2004.05.030","article-title":"Pathophysiology and treatment of functional dyspepsia","volume":"127","author":"Tack","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB16|cit16","first-page":"1441","article-title":"Measuring quality of life in clinical trials: a taxonomy and review","volume":"140","author":"Guyatt","year":"1989","journal-title":"Can Med J Assoc"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB17|cit17","first-page":"189","article-title":"The irritable bowel syndrome: toward optimal design of controlled treatment trials","volume":"6","author":"Talley","year":"1993","journal-title":"Gastroenterol Int"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/0021-9681(87)90080-4","article-title":"A comparison of Likert and Visual Analogue Scales for measuring change in function","volume":"40","author":"Guyatt","year":"1987","journal-title":"Chron Dis"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0197-2456(89)90005-6","article-title":"Measurement of health status: ascertaining the minimal clinically important difference","volume":"10","author":"Jaeschke","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/0895-4356(89)90128-5","article-title":"Responsiveness and validity in health status measurement: a clarification","volume":"42","author":"Guyatt","year":"1989","journal-title":"J Clin Epidemiol"},{"issue":"Suppl. 2","key":"10.1111\/j.1365-2036.2010.04566.x-BIB21|cit21","first-page":"1169","article-title":"Design of treatment trials for functionalgastrointestinal disorders","volume":"45","author":"Veldhuyzen van Zanten","year":"1999","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/BF00435438","article-title":"Responsiveness to change: an aspect of validity, not a separate dimension","volume":"1","author":"Hays","year":"1992","journal-title":"Qual Life Res"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0021-9681(85)90005-0","article-title":"A methodological framework for assessing health indices","volume":"38","author":"Kirshner","year":"1985","journal-title":"J Chron Dis"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0895-4356(99)00018-9","article-title":"Evaluation of a multidimensional measure of dyspepsia related health for use in a randomized clinical trial","volume":"52","author":"Cook","year":"1999","journal-title":"J Clin Epidemiol"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1080\/003655299750026029","article-title":"Patients with functional dyspepsia responding to omeprazole have a characteristic gastro-oesophageal reflux pattern","volume":"34","author":"Farup","year":"1999","journal-title":"Scan J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1046\/j.1365-2036.1999.00610.x","article-title":"Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist","volume":"13","author":"Camilleri","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/S0140-6736(00)02033-X","article-title":"Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomized, placebo-controlled trial","volume":"355","author":"Camilleri","year":"2000","journal-title":"Lancet"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1001\/archinte.161.14.1733","article-title":"A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhoea-predominant irritable bowel syndrome","volume":"161","author":"Camilleri","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"S277","DOI":"10.14309\/00000434-200410001-00846","article-title":"Cilansetron in irritable bowel syndrome with diarrhoea predominance (IBS-D); efficacy and safety in a 3\u2003month US study","volume":"99","author":"Miner","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"S279","DOI":"10.14309\/00000434-200410001-00852","article-title":"The potential dextofisopam for treatment of irritable bowel syndrome and the irritable bowel syndrome","volume":"99","author":"Leventer","year":"2004","journal-title":"Am J Gastroenterol"},{"issue":"Suppl. 2","key":"10.1111\/j.1365-2036.2010.04566.x-BIB31|cit31","first-page":"A42","article-title":"Cilansetron in irritable bowel syndrome with diarrhoea predominance (IBS-D): efficacy and safety in a 6\u2003month global study","volume":"126","author":"Bradette","year":"2004","journal-title":"Gastroenterology"},{"issue":"4 Suppl. 2","key":"10.1111\/j.1365-2036.2010.04566.x-BIB32|cit32","first-page":"A643","article-title":"Cilansetron, a novel 5-HT3 antagonist demonstrated efficacy in males with irritable bowel syndrome with diarrhoea-predominance (IBS-D)","volume":"126","author":"Coremans","year":"2004","journal-title":"Gastroenterology"},{"issue":"4 Suppl. 2","key":"10.1111\/j.1365-2036.2010.04566.x-BIB33|cit33","first-page":"A94","article-title":"The safety and efficacy of dextofisopam in patients with diarrhoea-predominant or alternating irritable bowel syndrome","volume":"128","author":"Leventer","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/gut.52.5.671","article-title":"An Asia-Pacific, double-blind, placebo controlled, randomized study to evaluate the efficacy, safety, and tolerability of tegaserod on patients with irritable bowel syndrome","volume":"52","author":"Kellow","year":"2003","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/00365520310006748","article-title":"A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome","volume":"39","author":"Nyhlin","year":"2004","journal-title":"Scand J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1365-2036.2004.02294.x","article-title":"Tegaserod is effective in the initial and re-treatment of irritable bowel syndrome with constipation","volume":"21","author":"Muller-Lissner","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1136\/gut.2005.070789","article-title":"A randomized controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation","volume":"54","author":"Tack","year":"2005","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/j.1365-2036.2006.02839.x","article-title":"Personal view: adequate relief as a primary endpoint in irritable bowel syndrome","volume":"23","author":"Mangel","year":"2006","journal-title":"Aliment Pharm Ther"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.cgh.2007.03.004","article-title":"Primary endpoints for FGID trials: a review of binary and integrated symptom assessments","volume":"5","author":"Camilleri","year":"2007","journal-title":"Clin Gastro Hepatol"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1046\/j.1365-2036.2001.00941.x","article-title":"A dose ranging placebo controlled randomized trial of alosetron in patients with functional dyspepsia","volume":"15","author":"Talley","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB41|cit41","first-page":"A467","article-title":"Therapeutic efficacy of novel agent (Z-338) in functional dyspepsia (FD)","volume":"130","author":"Matsueda","year":"2006","journal-title":"Gastroenterology"},{"issue":"Suppl. 1","key":"10.1111\/j.1365-2036.2010.04566.x-BIB42|cit42","doi-asserted-by":"crossref","first-page":"A-157","DOI":"10.1016\/S0016-5085(08)60732-5","article-title":"A Novel Acetylcholine Esterase Inhibitor Acotiamide Hydrochloride (YM443) in Functional Dyspepsia: efficacy in a randomized, double-blind, placebo-controlled dose ranging trial","volume":"134","author":"Talley","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB43|cit43","first-page":"1906","article-title":"Tegaserod treatment for functional dyspepsia dysmotility symptoms: results of two randomized, controlled trials","volume":"103","author":"Vakil","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB44|cit44","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/BF01540334","article-title":"Symptomatic, radionuclide and therapeutic assessment of chronic idiopathic dyspepsia. A double-blind placebo-controlled evaluation of cisapride","volume":"34","author":"Jian","year":"1989","journal-title":"Dig Dis Sci"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB45|cit45","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1365-2036.1992.tb00265.x","article-title":"Effect of treatment with cisapride alone or in combination with domperidone on gastric emptying and gastrointestinal symptoms in dyspeptic patients","volume":"6","author":"Tatsuta","year":"1992","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB46|cit46","first-page":"623","article-title":"Clinical trial on the effect of domperidone on non-ulcer dyspepsia","volume":"83","author":"Sarin","year":"1986","journal-title":"Indian J Med Res"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB47|cit47","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1155\/1997\/314839","article-title":"A double-blind randomized study of cisapride in the treatment of non-ulcer dyspepsia. The Canadian Cisapride Nud Study Group","volume":"11","author":"Champion","year":"1997","journal-title":"Can J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB48|cit48","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1046\/j.1365-2036.1997.117288000.x","article-title":"Cisapride in functional dyspepsia in general practice. A placebo-controlled, randomized, double-blind study","volume":"11","author":"De Groot","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB49|cit49","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1365-2982.2009.01261.x","article-title":"A dose-ranging, placebo-controlled, pilot trial of acotiamide in patients with functional dyspepsia","volume":"21","author":"Tack","year":"2009","journal-title":"Neurogastroenterol Motil"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB50|cit50","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3109\/00365528809093840","article-title":"Treatment with cimetidine, antacid or placebo in patients with dyspepsia of unknown origin","volume":"23","author":"Gotthard","year":"1988","journal-title":"Scand J Gastroenterol"},{"issue":"Suppl. 1","key":"10.1111\/j.1365-2036.2010.04566.x-BIB51|cit51","first-page":"30","article-title":"Domperidone in the treatment of functional dyspepsia in patients with delayed gastric emptying","volume":"55","author":"Bekhti","year":"1979","journal-title":"Postgrad Med"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB52|cit52","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000198352","article-title":"Oral domperidone in chronic postprandial dyspepsia","volume":"19","author":"Van de Mierop","year":"1979","journal-title":"Digestion"},{"issue":"Suppl. 1","key":"10.1111\/j.1365-2036.2010.04566.x-BIB53|cit53","first-page":"24","article-title":"A double-blind study of domperidone in the symptomatic treatment of chronic post-prandial upper gastrointestinal distress","volume":"55","author":"Haarmann","year":"1979","journal-title":"Postgrad Med J"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB54|cit54","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/00004836-198608000-00006","article-title":"A controlled trial of cimetidine for the treatment of non-ulcer dyspepsia","volume":"8","author":"Lance","year":"1986","journal-title":"J Clin Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB55|cit55","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1177\/030006059001800103","article-title":"Pirenzepine in non-ulcer dyspepsia: a double-blind multicentre trial","volume":"18","author":"Smith","year":"1990","journal-title":"J Int Med Res"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB56|cit56","first-page":"44","article-title":"Cisapride in the management of chronic functional dyspepsia: a multicentre, double-blind, placebo-controlled study","volume":"10","author":"Deruyttere","year":"1987","journal-title":"Clin Ther"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB57|cit57","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3109\/00365528708991874","article-title":"Cisapride in non ulcer dyspepsia. Results of a placebo-controlled trial","volume":"22","author":"Rosch","year":"1987","journal-title":"Scand J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB58|cit58","first-page":"814","article-title":"Efficacy of cisapride in patients with nonulcer dyspepsia. A placebo-controlled study","volume":"42","author":"Hannon","year":"1987","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB59|cit59","first-page":"261","article-title":"Cisapride in the treatment of chronic functional dyspepsia. Results of a double-blind, placebo-controlled, crossover study","volume":"42","author":"Goethals","year":"1987","journal-title":"Curr Ther Res"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB60|cit60","first-page":"891","article-title":"Nonulcer dyspepsia: effect of the gastrointestinal prokinetic drug cisapride","volume":"41","author":"Francois","year":"1987","journal-title":"Curr Ther Res"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB61|cit61","first-page":"62","article-title":"Relief of epigastric pain in nonulcer dyspepsia: controlled trial of the promotility drug cisapride","volume":"11","author":"De Nutte","year":"1989","journal-title":"Clin Ther"},{"issue":"Suppl. 195","key":"10.1111\/j.1365-2036.2010.04566.x-BIB62|cit62","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3109\/00365529309098322","article-title":"Cisapride in functional dyspepsia: a double-blind placebo-controlled randomized trial in general practice patients","volume":"28","author":"Wood","year":"1993","journal-title":"Scand J Gastroenterol"},{"issue":"Suppl.","key":"10.1111\/j.1365-2036.2010.04566.x-BIB63|cit63","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3109\/00365529309098323","article-title":"Cisapride in chronic dyspepsia: results of a double-blind, placebo-controlled trial","volume":"195","author":"Chung","year":"1993","journal-title":"Scand J Gastroenterol"},{"issue":"Suppl. 195","key":"10.1111\/j.1365-2036.2010.04566.x-BIB64|cit64","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3109\/00365529309098328","article-title":"Efficacy of cisapride in functional dyspepsia resistant to domperidone or metoclopramide: a double-blind placebo-controlled study","volume":"28","author":"Van Outryve","year":"1993","journal-title":"Scand J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB65|cit65","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3109\/00365529409090434","article-title":"Cisapride versus metoclopramide in the treatment of functional dyspepsia. A double-blind comparative trial","volume":"29","author":"Fumagalli","year":"1994","journal-title":"Scand J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB66|cit66","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3109\/00365529509089785","article-title":"A double-blind, randomized, placebo-controlled trial of cisapride in Saudi Arabs with functional dyspepsia","volume":"30","author":"Al-Quorain","year":"1995","journal-title":"Scand J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB67|cit67","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1365-2036.1995.tb00364.x","article-title":"Efficacy of cisapride therapy in functional dyspepsia","volume":"9","author":"Kellow","year":"1995","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB68|cit68","first-page":"411","article-title":"Cisapride compared with ranitidine in the treatment of functional dyspepsia","volume":"7","author":"Carvalhinhos","year":"1995","journal-title":"Euro J Gastroenterol and Hepatol"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB69|cit69","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1440-1746.1997.tb00338.x","article-title":"Effect of cisapride on functional dyspepsia in patients with and without histological gastritis: a double-blind placebo controlled trial","volume":"12","author":"Yeoh","year":"1997","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB70|cit70","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1572-0241.1998.00368.x","article-title":"Placebo-controlled trial of cisapride and nizatidine in unselected patients with functional dyspepsia","volume":"93","author":"Hansen","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB71|cit71","first-page":"1063","article-title":"Effect of the non-antidopaminergic drug cisapride on postprandial nausea","volume":"36","author":"Creytens","year":"1999","journal-title":"Curr Ther Res"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB72|cit72","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1046\/j.1365-2036.2000.00801.x","article-title":"Cisapride provides symptomatic relief in functional dyspepsia associated with gastric myoelectrical abnormality","volume":"14","author":"Chen","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB73|cit73","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1007\/BF02087560","article-title":"Double-blind dose-response multicenter comparison of fedotozine and placebo in treatment of nonulcer dyspepsia","volume":"39","author":"Fraitag","year":"1994","journal-title":"Dig Dis Sci"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB74|cit74","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1136\/gut.41.5.664","article-title":"Efficacy and safety of the peripheral kappa agonist fedotozine versus placebo in the treatment of functional dyspepsia","volume":"41","author":"Read","year":"1997","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB75|cit75","first-page":"980","article-title":"Symptomatic treatment of non-ulcer dyspepsia with cimetidine","volume":"37","author":"Delattre","year":"1985","journal-title":"Curr Ther Res"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB76|cit76","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.0954-6820.1985.tb02696.x","article-title":"Controlled clinical trial of treatment with cimetidine for non-ulcer dyspepsia","volume":"217","author":"Kelbaek","year":"1985","journal-title":"Acta Med Scand"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB77|cit77","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1185\/03007998909110140","article-title":"Cimetidine in the treatment of non-ulcer dyspepsia: results of a randomized double-blind, placebo-controlled study","volume":"11","author":"Singal","year":"1989","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB78|cit78","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0002-9343(87)90828-X","article-title":"Sucralfate versus placebo in treatment of non-ulcer dyspepsia","volume":"83","author":"Kairaluoma","year":"1987","journal-title":"Am J Med"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB79|cit79","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1136\/gut.30.9.1206","article-title":"Campylobacter associated gastritis in patients with non-ulcer dyspepsia: a double blind placebo controlled trial with colloidal bismuth subcitrate","volume":"30","author":"Loffeld","year":"1989","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB80|cit80","first-page":"400","article-title":"Double blind trial of colloidal bismuth subcitrate versus placebo in Helicobacter pylori positive patients with non-ulcer dyspepsia","volume":"24","author":"Vaira","year":"1992","journal-title":"Italian J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB81|cit81","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.3109\/00365529008997630","article-title":"Misoprostol treatment exacerbates abdominal discomfort in patients with non-ulcer dyspepsia and erosive pyloric changes. A double-blind, placebo-controlled multicentre study","volume":"25","author":"Hausken","year":"1990","journal-title":"Scand J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB82|cit82","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1080\/003655202762671260","article-title":"Effect of profound acid suppression in functional dyspepsia: a double-blind, randomized, placebo-controlled trial","volume":"37","author":"Bolling-Sternevald","year":"2002","journal-title":"Scand J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB83|cit83","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.amjmed.2004.01.008","article-title":"Lansoprazole in the treatment of functional dyspepsia: two double-blind, randomized, placebo-controlled trials","volume":"116","author":"Peura","year":"2004","journal-title":"Am J Med"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB84|cit84","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1136\/gut.47.4.473","article-title":"Short course acid suppressive treatment for patients with functional dyspepsia: results depend on Helicobacter pylori status","volume":"47","author":"Blum","year":"2000","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB85|cit85","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1046\/j.1365-2036.2000.00868.x","article-title":"Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double-blind placebo-controlled trial","volume":"14","author":"Talley","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB86|cit86","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1046\/j.1365-2036.2002.01236.x","article-title":"Dose finding study of mosapride in functional dyspepsia: a placebo-controlled, randomized study","volume":"16","author":"Hallerback","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB87|cit87","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1046\/j.1365-2036.2003.01767.x","article-title":"Efficacy of artichoke leaf extract in the treatment of patients with functional dyspepsia: a six-week placebo-controlled, double-blind multicentre trial","volume":"18","author":"Holtmann","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB88|cit88","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1046\/j.1365-2036.1998.00410.x","article-title":"Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies)","volume":"12","author":"Talley","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB89|cit89","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJM199812243392602","article-title":"Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group","volume":"339","author":"Blum","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB90|cit90","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1136\/bmj.318.7187.833","article-title":"Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trial with 12\u2003months\u2019 follow up. The Optimal Regimen Cures Helicobacter Induced Dyspepsia (ORCHID) Study group","volume":"318","author":"Talley","year":"1999","journal-title":"BMJ"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB91|cit91","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1056\/NEJMoa052639","article-title":"A placebo-controlled trial of itopride in functional dyspepsia","volume":"354","author":"Holtmann","year":"2006","journal-title":"N Eng J Med"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB92|cit92","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1136\/gut.2007.132449","article-title":"Itopride in Functional Dyspepsia: results of two phase III multicenter, randomized, double-blind, placebo-controlled trials","volume":"57","author":"Talley","year":"2008","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB93|cit93","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0895-4356(93)90075-C","article-title":"Can severity of symptoms be used as outcome measures in trials of non-ulcer dyspepsia and Helicobacter pylori associated gastritis?","volume":"46","author":"Veldhuyzen van Zanten","year":"1993","journal-title":"J Clin Epidemiol"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB94|cit94","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1111\/j.1572-0241.2005.40280.x","article-title":"A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in Helicobacter pylori negative, primary care patients with dyspepsia: the CADET-HN study","volume":"100","author":"Veldhuyzen van Zanten","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB95|cit95","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1136\/bmj.324.7344.1012","article-title":"Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive (CADET-HP) randomised controlled trial","volume":"324","author":"Chiba","year":"2002","journal-title":"BMJ"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB96|cit96","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/j.1365-2036.2005.02466.x","article-title":"Heartburn-dominant, uninvestigated dyspepsia: a comparison of \u2018PPI-Start\u2019 and \u2018H2-RA-Start\u2019 management strategies in primary care. The CADET-HR Study","volume":"21","author":"Armstrong","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB97|cit97","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1111\/j.1572-0241.2006.00751.x","article-title":"Esomeprazole 40\u2003mg once a day in patients with functional dyspepsia: the Randomized, Placebo-Controlled \u201cENTER\u201d Trial","volume":"101","author":"Veldhuyzen van Zanten","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB98|cit98","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/j.1365-2982.2009.01449.x","article-title":"Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia - 100\u2003mg t.i.d. is an optimal","volume":"22","author":"Matsueda","year":"2010","journal-title":"Neurogastroenterol Motil"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB99|cit99","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3109\/00365528809103974","article-title":"Low dose antacids and pirenzipine in the treatment of patients with nonulcer dyspepsia and erosive prepyloric changes. A randomized, double-blind, placebo-controlled trial","volume":"23","author":"Weberg","year":"1988","journal-title":"Scand J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB100|cit100","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3109\/00365528809093874","article-title":"Cimetidine responders in non-ulcer dyspepsia","volume":"23","author":"Johannessen","year":"1988","journal-title":"Scan J Gastroenterol"},{"issue":"Suppl. 2","key":"10.1111\/j.1365-2036.2010.04566.x-BIB101|cit101","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1365-2036.2005.02471.x","article-title":"Usefulness of famotidine in functional dyspepsia patient treatment: comparison among prokinetic, acid suppression and antianxiety therapies","volume":"21","author":"Seno","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB102|cit102","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3109\/00365529208999951","article-title":"Cisapride treatment of patients with non-ulcer dyspepsia and erosive prepyloric changes. A double-blind, placebo-controlled trial","volume":"27","author":"Hausken","year":"1992","journal-title":"Scan J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB103|cit103","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1046\/j.1365-2036.2000.00873.x","article-title":"Efficacy and tolerability of a fixed combination of peppermint oil and caraway oil in patients suffering from functional dyspepsia","volume":"14","author":"May","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB104|cit104","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1046\/j.1365-2036.2002.01322.x","article-title":"A randomized placebo-controlled trial of simethicone and cisapride for the treatment of patients with functional dyspepsia","volume":"16","author":"Holtmann","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB105|cit105","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1365-2036.2006.02774.x","article-title":"Validation of a 7-point global overall symptom (GOS) scale to measure the severity of dyspepsia symptoms in clinical trials","volume":"23","author":"Veldhuyzen van Zanten","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"issue":"9 Suppl. 1","key":"10.1111\/j.1365-2036.2010.04566.x-BIB106|cit106","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1016\/S0002-9270(03)00909-2","article-title":"Symptom response at 1-week predicts responders at 4-weeks with esomeprazole (40\u2003mg bid and od) in patients with uninvestigated dyspepsia","volume":"98","author":"Armstrong","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB107|cit107","first-page":"41","article-title":"Quality of life in reflux and dyspepsia patients. Psychometric documentation of a new disease-specific questionnaire (QOLRAD)","volume":"583","author":"Wiklund","year":"1998","journal-title":"Eur J Surg"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB108|cit108","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/BF01535722","article-title":"GSRS-a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease","volume":"33","author":"Svedlund","year":"1988","journal-title":"Dig Dis Sci"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB109|cit109","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1572-0241.2001.03451.x","article-title":"Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease","volume":"96","author":"Shaw","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB110|cit110","doi-asserted-by":"crossref","first-page":"681","DOI":"10.3109\/00365529309098272","article-title":"Quality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens?","volume":"28","author":"Dimenas","year":"1993","journal-title":"Scand J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB111|cit111","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1023\/A:1008841022998","article-title":"Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease","volume":"7","author":"Revicki","year":"1998","journal-title":"Qual Life Res"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB112|cit112","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1046\/j.1365-2036.2001.01074.x","article-title":"Double-blind placebo-controlled multicentre studies of rebamipide, a gastroprotective drug, in the treatment of functional dyspepsia with or without Helicobacter pylori infection","volume":"15","author":"Talley","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB113|cit113","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1038\/ajg.2009.427","article-title":"Efficacy of the 5-HT1A agonist tandospirone citrate in improving symptoms of patients with functional dyspepsia: a randomized controlled trial","volume":"104","author":"Miwa","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB114|cit114","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1046\/j.1365-2036.1998.00404.x","article-title":"The Leeds Dyspepsia Questionnaire: a valid tool for measuring the presence and severity of dyspepsia","volume":"12","author":"Moayyedi","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB115|cit115","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1365-2036.2006.03233.x","article-title":"The Short-Form Leeds Dyspepsia Questionnaire validation study","volume":"25","author":"Fraser","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB116|cit116","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1023\/A:1005558204440","article-title":"Patient-based assessment in dyspepsia: development and validation of Dyspepsia Symptom Severity Index (DSSI)","volume":"45","author":"Leidy","year":"2000","journal-title":"Dig Dis Sci"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB117|cit117","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1046\/j.1440-1746.2002.02713.x","article-title":"The Hong Kong index of dyspepsia: a validated symptom severity questionnaire for patients with dyspepsia","volume":"17","author":"Hu","year":"2002","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB118|cit118","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1136\/gut.51.4.502","article-title":"Double blind, randomised placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients","volume":"51","author":"Wong","year":"2002","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB119|cit119","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1007\/s10620-004-9578-z","article-title":"Development and validation of a cross-cultural questionnaire to evaluate nonulcer dyspepsia: The Porto Alegre Dyspeptic Symptoms Questionnaire (PADYQ)","volume":"49","author":"Sander","year":"2004","journal-title":"Dig Dis Sci"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB120|cit120","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1365-2036.1999.00445.x","article-title":"Development of a new dyspepsia impact scale: the Nepean Dyspepsia Index","volume":"13","author":"Talley","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB121|cit121","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1111\/j.1572-0241.1999.01363.x","article-title":"Validity of a new quality of life scale for functional dyspepsia: a United States multicentre trial of the Nepean Dyspepsia Index (NDI)","volume":"94","author":"Talley","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB122|cit122","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1136\/gut.2005.078634","article-title":"Functional dyspepsia, delayed gastric emptying, and impaired quality of life","volume":"55","author":"Talley","year":"2006","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB123|cit123","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1111\/j.1572-0241.1999.01363.x","article-title":"Validity of a new quality of life scale for functional dyspepsia: a United States multicenter trial of the Nepean Dyspepsia Index","volume":"94","author":"Talley","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB124|cit124","first-page":"1554","article-title":"Initial linguistic and psychometric validation of the Arabic version of Nepean Dyspepsia Index","volume":"27","author":"Khalil","year":"2006","journal-title":"Saudi Med J"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB125|cit125","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1046\/j.1365-2036.2001.00900.x","article-title":"Quality of life in functional dyspepsia: responsiveness of the Nepean Dyspepsia Index and development of a new 10-item short form","volume":"15","author":"Talley","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB126|cit126","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0895-4356(00)00365-6","article-title":"SODA (Severity of Dyspepsia Assessment): a new effective outcome measure for dyspepsia-related health","volume":"54","author":"Rabeneck","year":"2001","journal-title":"J Clin Epi"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB127|cit127","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1572-0241.2002.05419.x","article-title":"Reliability, validity, and responsiveness of severity of dyspepsia assessment (SODA) in a randomized clinical trial of a COX-2-specific inhibitor and traditional NSAID therapy","volume":"97","author":"Rabeneck","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB128|cit128","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s11136-004-9567-x","article-title":"Development and psychometric evaluation of the patient assessment of upper gastrointestinal symptom severity index (PAGI-SYM) in patients with upper gastrointestinal disorders","volume":"13","author":"Rentz","year":"2004","journal-title":"Qual Life Res"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB129|cit129","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S1542-3565(04)00348-9","article-title":"Responsiveness and interpretation of a symptom severity index specific to upper gastrointestinal disorders","volume":"2","author":"Revicki","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB130|cit130","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1365-2982.2008.01260.x","article-title":"A placebo-controlled trial of the 5-HT1A agonist R-137696 on symptoms, visceral hypersensitivity and on impaired accommodation in functional dyspepsia","volume":"21","author":"Tack","year":"2009","journal-title":"Neurogastroenterol Motil"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB131|cit131","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S1542-3565(04)00349-0","article-title":"Responsiveness and interpretation of a quality of life questionnaire specific to upper gastrointestinal disorders","volume":"2","author":"De La Loge","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB132|cit132","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1097\/00042737-199610000-00006","article-title":"The Glasgow dyspepsia severity score-a tool for the global measurement of dyspepsia","volume":"8","author":"El-Omar","year":"1996","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB133|cit133","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1056\/NEJM199812243392601","article-title":"Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia","volume":"339","author":"McColl","year":"1998","journal-title":"N Eng J Med"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB134|cit134","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1097\/00042737-200012080-00016","article-title":"Validation of phone interview for follow-up in clinical trials on dyspepsia: evaluation of the Glasgow Dyspepsia Severity Score and a Likert-scale symptoms test","volume":"12","author":"Calvet","year":"2000","journal-title":"Eur J Gasatroenterol Hepatol"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB135|cit135","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/0895-4356(95)00584-6","article-title":"Developing a condition-specific measure of health for patients with dyspepsia and ulcer-related symptoms","volume":"49","author":"Garratt","year":"1996","journal-title":"J Clin Epidemiol"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB136|cit136","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1365-2036.2005.02572.x","article-title":"Validation of the gastrointestinal symptom score for the assessment of symptoms in patients with functional dyspepsia","volume":"22","author":"Adam","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB137|cit137","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000076546","article-title":"Treatment of functional dyspepsia with a herbal preparation. A doubleblind, randomized, placebo-controlled, multicenter trial","volume":"69","author":"Madisch","year":"2004","journal-title":"Digestion"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB138|cit138","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1055\/s-2002-32130","article-title":"A randomised clinical trial comparing the efficacy of a herbal preparation STW 5 with the prokinetic drug cisapride in patients with dysmotility type of functional dyspepsia","volume":"40","author":"Rosch","year":"2002","journal-title":"Z Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB139|cit139","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1055\/s-2001-16142","article-title":"A plant extract and its modified preparation in functional dyspepsia. Results of a double-blind placebo controlled comparative study","volume":"39","author":"Madisch","year":"2001","journal-title":"Z Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB140|cit140","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1097\/00005650-198807000-00007","article-title":"The MOS short-form general health survey. Reliability and validity in a patient population","volume":"26","author":"Stewart","year":"1988","journal-title":"Med Care"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB141|cit141","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1023\/A:1018831127942","article-title":"Quality of life in persons with irritable bowel syndrome. Development and validation of a new measure","volume":"43","author":"Patrick","year":"1998","journal-title":"Dig Dis Sci"},{"issue":"Suppl. 2","key":"10.1111\/j.1365-2036.2010.04566.x-BIB142|cit142","first-page":"A94","article-title":"Work productivity and daily activity impairment in patients with functional dyspepsia: double-blind comparison of tegaserod vs placebo","volume":"132","author":"Laine","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB143|cit143","first-page":"435","volume-title":"Balliere\u2019s Clinical Gastroenterology","author":"Locke","year":"1998"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB144|cit144","first-page":"829","article-title":"Non ulcer dyspepsia in the long term perspective","volume":"7","author":"Lindell","year":"1995","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB145|cit145","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/00004836-199806000-00022","article-title":"Meta analysis of antisecretory and gastrokinetic compounds in functional dyspepsia","volume":"26","author":"Finney","year":"1998","journal-title":"J Clin Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB146|cit146","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/0016-5085(88)90319-8","article-title":"Controlled treatment trials in the irritable bowel syndrome: A critique","volume":"95","author":"Klein","year":"1988","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB147|cit147","first-page":"1","article-title":"Pharmacological interventions for non-ulcer dyspepsia","volume":"4","author":"Moayyedi","year":"2006","journal-title":"Coch Datab Syst Rev"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB148|cit148","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1046\/j.1365-2036.1999.00505.x","article-title":"A double-blind, placebo-controlled study of the efficacy and safety of non-prescription ranitidine 75\u2003mg in the prevention of meal-induced heartburn","volume":"13","author":"Pappa","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB149|cit149","unstructured":"FDA Gastrointestinal Drugs Advisory Committee Transcript from FDA Gastrointestinal Drugs Advisory Committee 1999"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB150|cit150","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1177\/030006059802600203","article-title":"Adequate relief as an endpoint in clinical trials in irritable bowel syndrome","volume":"26","author":"Mangel","year":"1998","journal-title":"J Int Med Res"},{"issue":"Suppl. 2","key":"10.1111\/j.1365-2036.2010.04566.x-BIB151|cit151","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1046\/j.1365-2036.1999.00010.x","article-title":"Review article: safety and efficacy of alosetron, a 5-HT3 receptor antagonist, in female irritable bowel syndrome patients","volume":"13","author":"Mangel","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB152|cit152","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/j.1572-0241.2006.00535.x","article-title":"Reports of \u201csatisfactory relief\u201d by IBS patients receiving usual medical care are confounded by baseline symptom severity and do not accurately reflect symptom improvement","volume":"101","author":"Whitehead","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04566.x-BIB153|cit153","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1046\/j.1365-2036.2003.01709.x","article-title":"Clinical trial guidelines for pharmacological treatment of irritable bowel syndrome","volume":"18","author":"Corazziari","year":"2003","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2010.04566.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2036.2010.04566.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T17:49:10Z","timestamp":1625420950000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2010.04566.x"}},"subtitle":["Review: dyspepsia endpoints for use in drug therapy trials"],"short-title":[],"issued":{"date-parts":[[2011,1,12]]},"references-count":153,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,3]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2010.04566.x","relation":{},"ISSN":["0269-2813"],"issn-type":[{"value":"0269-2813","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1,12]]}}}